长春高新产品调价第四季预亏10亿 年投超20亿研发欲摆脱生长激素依赖

Core Viewpoint - Changchun High-tech (000661.SZ) is expected to experience a significant decline in operating performance, with a projected net profit attributable to shareholders of 150 million to 220 million yuan for 2025, representing a year-on-year decrease of over 90% [1][4]. Group 1: Financial Performance - In 2024, Changchun High-tech's net profit attributable to shareholders decreased by over 40% year-on-year [2]. - For 2025, the company anticipates a net profit drop of 24.33 billion to 23.63 billion yuan compared to the previous year, with a decline rate of 91.48% to 94.19% [4]. - The company reported a net profit of 1.165 billion yuan for the first three quarters of 2025, down 58.23% year-on-year, with total revenue of 9.807 billion yuan, a decrease of 5.60% [4]. Group 2: Factors Influencing Performance - The decline in net profit is attributed to adjustments in pricing and sales policies for core products, particularly long-acting growth hormones, due to their inclusion in the national medical insurance directory [2][6]. - Increased research and development (R&D) expenses, which reached 2.690 billion yuan in 2024, and higher sales expenses have also impacted profitability [10][12]. - The company is focusing on R&D in traditional areas such as endocrine metabolism and women's health, as well as innovative directions related to tumors, respiratory, and immune systems [10]. Group 3: R&D and Product Development - Changchun High-tech's R&D investment for the first three quarters of 2025 was 1.733 billion yuan, a year-on-year increase of 22.91% [12]. - The company has successfully advanced several products, including the GenSci098 injection project, which received a 70 million USD upfront payment [3][14]. - The R&D expenses have been steadily increasing, with a total of 2.690 billion yuan in 2024, representing 19.97% of total revenue [10]. Group 4: Market Position and Future Outlook - The company has historically relied heavily on growth hormones, which have been referred to as its "cash cow" [6]. - The future ability of Changchun High-tech to reduce its dependence on growth hormones is a key concern for investors [15].